Open-Label, Long-Term Safety Study of Cevimeline in the Treatment of Postirradiation Xerostomia

Cevimeline 45 mg t.i.d. was generally well tolerated over a period of 52 weeks in subjects with xerostomia secondary to radiotherapy for cancer in the head-and-neck region.